You are here: Home » News-CM » Companies » News
Business Standard

Alembic Pharmaceuticals receives USFDA approval for Candesartan Cilexetil Tablets U

Capital Market 

has received approval from the (USFDA) for its Application (ANDA) Cilexetil Tablets USP, 4 mg, 8 mg, and 16 mg.

The approved ANDA is therapeutically equivalent to the reference listed (RLD), Atacand Tablets, 4 mg, 8 mg, and 16 mg, of ANI Pharmaceuticals, Irie. cilexetil tablets are indicated for the treatment of in adults and in children 1 to <17 years of age, to lower blood pressure. cilexetil tablets also indicated for the

Candesartan Cilexetil Tablets USP, 4 mg, 8 mg, and 16 mg, hzve an estimated market size of US$ 22 million for twelve months ending December 2017 according to IQVIA.

Alembic has a cumulative total of 82 ANDA approvals (69 final approvals and 13 tentative approvals) from USFDA.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, December 05 2018. 11:07 IST